In:
Proteins: Structure, Function, and Bioinformatics, Wiley, Vol. 91, No. 8 ( 2023-08), p. 1021-1031
Abstract:
The rapid adaptation of SARS‐CoV‐2 within the host species and the increased viral transmission triggered the evolution of different SARS‐CoV‐2 variants. Though numerous monoclonal antibodies (mAbs) have been identified as prophylactic therapy for SARS‐CoV‐2, the ongoing surge in the number of SARS‐CoV‐2 infections shows the importance of understanding the mutations in the spike and developing novel vaccine strategies to target all variants. Here, we report the map of experimentally validated 74 SARS‐CoV‐2 neutralizing mAb binding epitopes of all variants. The majority (87.84%) of the potent neutralizing epitopes are localized to the receptor‐binding domain (RBD) and overlap with each other, whereas limited (12.16%) epitopes are found in the N‐terminal domain (NTD). Notably, 69 out of 74 mAb targets have at least one mutation at the epitope sites. The potent epitopes found in the RBD show higher mutations (4‐10aa) compared to lower or modest neutralizing antibodies, suggesting that these epitopes might co‐evolve with the immune pressure. The current study shows the importance of determining the critical mutations at the antibody recognition epitopes, leading to the development of broadly reactive immunogens targeting multiple SARS‐CoV‐2 variants. Further, vaccines inducing both humoral and cell‐mediated immune responses might prevent the escape of SARS‐CoV‐2 variants from neutralizing antibodies.
Type of Medium:
Online Resource
ISSN:
0887-3585
,
1097-0134
Language:
English
Publisher:
Wiley
Publication Date:
2023
detail.hit.zdb_id:
1475032-6
SSG:
12
Permalink
